Ali Fattaey - Curis CEO and President and Director
| CRIS Stock | USD 15.01 0.16 1.08% |
CEO
Dr. Ali Fattaey, Ph.D., is President, Chief Executive Officer, Director of Curis, Inc. He has served on our board since June 2014 and has served as President and Chief Executive Officer since June 2014. From February 2013 to June 2014, Dr. Fattaey served as our President and Chief Operating Officer. Dr. Fattaey served as the President and Chief Executive Officer of ACT Biotech, Inc., a biotechnology company from January 2011 until February 2013 and as Chief Operating and Scientific Officer at ACT Biotech from February 2008 until December 2010. From June 2006 until January 2008, Dr. Fattaey served as the Director, Science and Technology at the Melanoma Therapeutics Foundation, a nonprofit organization. From January 2005 until June 2006, Dr. Fattaey was a strategic consultant. From November 2001 until April 2004, Dr. Fattaey served as the Chief Scientific Officer of Sagres Discovery, a biotechnology company, and as the Senior Vice President of Discovery Research at Chiron Corporationrationration, a biotechnology company, following Chirons acquisition of Sagres Discovery from May 2004 until January 2005. Dr. Fattaey was employed at Onyx Pharmaceuticals, a biopharmaceutical company, from January 1994 until June 2001, and held the position of Vice President of Discovery Research from August 1998 until June 2001. Dr. Fattaey also serves as a director of EpiTherapeutics ApS, a Danish biotechnology company since 2014.
| Age | 51 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | Building C, Lexington, MA, United States, 02421 |
| Phone | 617 503 6500 |
| Web | https://www.curis.com |
Curis Management Efficiency
The company has return on total asset (ROA) of (0.3246) % which means that it has lost $0.3246 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4319) %, meaning that it created substantial loss on money invested by shareholders. Curis' management efficiency ratios could be used to measure how well Curis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to drop to -0.8 in 2024. At this time, Curis' Total Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 64.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.3 M in 2024.Similar Executives
| Found 13 records | CEO Age | ||
| Stephen JD | Pieris Pharmaceuticals | 48 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| James Noble | Adaptimmune Therapeutics Plc | 54 | |
| Joseph Yanchik | Aileron Therapeutics | 51 | |
| Aleksandrs Sviks | Pieris Pharmaceuticals | 39 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| John Longenecker | Aileron Therapeutics | 57 | |
| Adi Hoess | Affimed NV | 63 | |
| Adrian Rawcliffe | Adaptimmune Therapeutics Plc | 52 | |
| Stephen Yoder | Pieris Pharmaceuticals | 38 | |
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
Management Performance
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.32 |
Curis Inc Leadership Team
Elected by the shareholders, the Curis' board of directors comprises two types of representatives: Curis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curis. The board's role is to monitor Curis' management team and ensure that shareholders' interests are well served. Curis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Rubin, Independent Director | ||
| James McNab, Independent Chairman of the Board | ||
| Kenneth Kaitin, Independent Director | ||
| Mani Mohindru, Vice President - Corporate Strategy and Investor Relations | ||
| Jonathan Zung, Chief Officer | ||
| Robert Martell, Independent Director | ||
| Reinhard MD, Senior Development | ||
| Kenneth Pienta, Director | ||
| David Tuck, Senior Vice President Chief Medical Officer | ||
| Lori Kunkel, Director | ||
| Ali Fattaey, CEO and President and Director | ||
| Elif McDonald, VP Communications | ||
| James Dentzer, CFO, Chief Administrative Officer, Treasurer, Secretary | ||
| Mark Noel, Vice Property | ||
| Martyn Greenacre, Independent Director | ||
| Daniel Passeri, Vice Chairman of the Board | ||
| Michael Gray, CFO, Principal Accounting Officer, Chief Bus. Officer and Secretary | ||
| Jaye Viner, Chief Medical Officer, Executive Vice President |
Curis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Curis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (4.52) % | ||||
| Current Valuation | 76.59 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Shares Owned By Insiders | 0.18 % | ||||
| Shares Owned By Institutions | 36.33 % | ||||
| Number Of Shares Shorted | 50.1 K | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 4.58 X |
Pair Trading with Curis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Curis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Curis will appreciate offsetting losses from the drop in the long position's value.Moving together with Curis Stock
| 0.64 | ELYM | Eliem Therapeutics | PairCorr |
| 0.91 | ACB | Aurora Cannabis Trending | PairCorr |
Moving against Curis Stock
| 0.82 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.65 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
| 0.62 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Curis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Curis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Curis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Curis Inc to buy it.
The correlation of Curis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Curis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Curis Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Curis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curis Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Curis Stock analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Curis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Curis. If investors know Curis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Curis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.96) | Revenue Per Share 1.894 | Quarterly Revenue Growth (0.07) | Return On Assets (0.32) | Return On Equity (1.43) |
The market value of Curis Inc is measured differently than its book value, which is the value of Curis that is recorded on the company's balance sheet. Investors also form their own opinion of Curis' value that differs from its market value or its book value, called intrinsic value, which is Curis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Curis' market value can be influenced by many factors that don't directly affect Curis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Curis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Curis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Curis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.